We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Ensign Group Shares Are Attracting Investors Now
Read MoreHide Full Article
Key Takeaways
Ensign Group operates 378 healthcare facilities across 17 states, including 31 senior living locations.
ENSG's 2026 earnings estimate is $7.48 per share with revenues projected at $5.8 billion.
ENSG expands through acquisitions, facility upgrades and stronger hospital ties to boost patient volumes.
The Ensign Group, Inc. (ENSG - Free Report) is well-poised for growth, benefiting from a combination of disciplined acquisitions, organic operational improvement and targeted capital investments in healthcare facilities. It has been expanding its portfolio, which now includes 378 healthcare operations, featuring 31 senior living facilities, spread across 17 states.
Headquartered in San Juan Capistrano, CA, ENSG holds a market capitalization of $11.9 billion. The company operates through two reportable segments: Skilled Services and Standard Bearer. It has risen 58% over the past year, outperforming the industry’s average gain of 56.4%.
Courtesy of solid prospects, ENSG currently carries a Zacks Rank #2 (Buy).
Where Do Estimates for ENSG Stand?
The Zacks Consensus Estimate for Ensign Group’s 2026 earnings is pegged at $7.48 per share, indicating a 13.9% year-over-year rise. In the past seven days, it has witnessed one upward estimate revision against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $5.8 billion for 2026, implying a 14.1% year-over-year rise. It beat earnings estimates in each of the past four quarters, with an average surprise of 2.9%.
The Ensign Group, Inc. Price, Consensus and EPS Surprise
Ensign Group’s revenue growth hinges on expanding service revenues from its specialized healthcare portfolio, including skilled nursing, rehabilitation and senior living. The aging U.S. demographic sustains robust demand for these services, bolstering the company's long-term prospects. In 2025, its total revenues rose 18.7% year over year, with 18.8% growth in Service revenues.
ENSG continues to expand by purchasing skilled nursing and post-acute care facilities in multiple markets, often targeting assets with turnaround potential or long-term upside. Recent entries into Alabama and additional acquisitions across Arizona, Washington, California, Idaho, Texas and Wisconsin highlight continued expansion of regional clusters. By integrating these operations into its decentralized model, the company aims to enhance performance through better clinical systems, leadership and local management expertise.
Ensign Group focuses heavily on improving clinical outcomes and building strong relationships with hospitals and healthcare providers in its communities. Better clinical performance helps the company attract more patients and gain the trust of hospitals and health plans, which in turn increases patient volumes and allows facilities to treat more medically complex cases.
Capital investments also play a role in supporting long-term expansion. The company continues to upgrade facilities, add beds and develop new healthcare infrastructure in markets where demand is rising. These initiatives help expand treatment capacity and improve care delivery while allowing Ensign Group to strengthen its presence in established regions.
Ensign Group’s capital strategy supports steady value creation through dividend payments and selective share repurchases. The company has raised its dividend for 23 consecutive years, including a December 2025 increase to 6.5 cents per share. It repurchased shares worth $20 million in 2025. Its total debt is 6% of its capital, which is significantly lower than the industry’s average of 89.7%.
ENSG: Risks to Watch
There are some factors, however, that investors should keep a careful eye on.
The company’s total expenses have escalated over the last several years due to higher costs of services and rent. Total expenses witnessed a year-over-year increase of 12.3% in 2024 and 18.7% in 2025. We expect total expenses to rise 13.6% year over year in 2026. The persistent escalation of expenses might weigh on its margin growth. Ensign Group's valuation looks expensive at the current level. It has a forward 12-month P/S ratio of 2.07X, which compares unfavorably with its five-year median of 1.58X.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.61 per share has witnessed seven upward revisions in the past seven days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 40.4%. The consensus estimate for current-year revenues is pegged at $14.8 billion, suggesting 14.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 75 cents per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for current-year revenues is pegged at $545 million, suggesting 27.5% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.02 per share has witnessed four upward revisions in the past 30 days, against no movement in the opposite direction. Phibro Animal Health beat earnings estimates in each of the trailing four quarters, with an average surprise of 20.2%. The consensus estimate for current-year revenues is pegged at $1.5 billion, suggesting 14.4% year-over-year growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Here's Why Ensign Group Shares Are Attracting Investors Now
Key Takeaways
The Ensign Group, Inc. (ENSG - Free Report) is well-poised for growth, benefiting from a combination of disciplined acquisitions, organic operational improvement and targeted capital investments in healthcare facilities. It has been expanding its portfolio, which now includes 378 healthcare operations, featuring 31 senior living facilities, spread across 17 states.
Headquartered in San Juan Capistrano, CA, ENSG holds a market capitalization of $11.9 billion. The company operates through two reportable segments: Skilled Services and Standard Bearer. It has risen 58% over the past year, outperforming the industry’s average gain of 56.4%.
Courtesy of solid prospects, ENSG currently carries a Zacks Rank #2 (Buy).
Where Do Estimates for ENSG Stand?
The Zacks Consensus Estimate for Ensign Group’s 2026 earnings is pegged at $7.48 per share, indicating a 13.9% year-over-year rise. In the past seven days, it has witnessed one upward estimate revision against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $5.8 billion for 2026, implying a 14.1% year-over-year rise. It beat earnings estimates in each of the past four quarters, with an average surprise of 2.9%.
The Ensign Group, Inc. Price, Consensus and EPS Surprise
The Ensign Group, Inc. price-consensus-eps-surprise-chart | The Ensign Group, Inc. Quote
ENSG’s Growth Drivers
Ensign Group’s revenue growth hinges on expanding service revenues from its specialized healthcare portfolio, including skilled nursing, rehabilitation and senior living. The aging U.S. demographic sustains robust demand for these services, bolstering the company's long-term prospects. In 2025, its total revenues rose 18.7% year over year, with 18.8% growth in Service revenues.
ENSG continues to expand by purchasing skilled nursing and post-acute care facilities in multiple markets, often targeting assets with turnaround potential or long-term upside. Recent entries into Alabama and additional acquisitions across Arizona, Washington, California, Idaho, Texas and Wisconsin highlight continued expansion of regional clusters. By integrating these operations into its decentralized model, the company aims to enhance performance through better clinical systems, leadership and local management expertise.
Ensign Group focuses heavily on improving clinical outcomes and building strong relationships with hospitals and healthcare providers in its communities. Better clinical performance helps the company attract more patients and gain the trust of hospitals and health plans, which in turn increases patient volumes and allows facilities to treat more medically complex cases.
Capital investments also play a role in supporting long-term expansion. The company continues to upgrade facilities, add beds and develop new healthcare infrastructure in markets where demand is rising. These initiatives help expand treatment capacity and improve care delivery while allowing Ensign Group to strengthen its presence in established regions.
Ensign Group’s capital strategy supports steady value creation through dividend payments and selective share repurchases. The company has raised its dividend for 23 consecutive years, including a December 2025 increase to 6.5 cents per share. It repurchased shares worth $20 million in 2025. Its total debt is 6% of its capital, which is significantly lower than the industry’s average of 89.7%.
ENSG: Risks to Watch
There are some factors, however, that investors should keep a careful eye on.
The company’s total expenses have escalated over the last several years due to higher costs of services and rent. Total expenses witnessed a year-over-year increase of 12.3% in 2024 and 18.7% in 2025. We expect total expenses to rise 13.6% year over year in 2026. The persistent escalation of expenses might weigh on its margin growth. Ensign Group's valuation looks expensive at the current level. It has a forward 12-month P/S ratio of 2.07X, which compares unfavorably with its five-year median of 1.58X.
Other Stocks to Consider
Some other top-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , GeneDx Holdings Corp (WGS - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.61 per share has witnessed seven upward revisions in the past seven days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 40.4%. The consensus estimate for current-year revenues is pegged at $14.8 billion, suggesting 14.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 75 cents per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for current-year revenues is pegged at $545 million, suggesting 27.5% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.02 per share has witnessed four upward revisions in the past 30 days, against no movement in the opposite direction. Phibro Animal Health beat earnings estimates in each of the trailing four quarters, with an average surprise of 20.2%. The consensus estimate for current-year revenues is pegged at $1.5 billion, suggesting 14.4% year-over-year growth.